PE2

9-(4-HYDROXY-3-(HYDROXYMETHYL)BUT-1-YL)GUANINE

PE2 as a free ligand exists in 1 entry. Examples include: 1KI3

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo



Chemical Component Summary

Name9-(4-HYDROXY-3-(HYDROXYMETHYL)BUT-1-YL)GUANINE
Identifiers2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1H-purin-6-one
FormulaC10 H15 N5 O3
Molecular Weight253.26
TypeNON-POLYMER
Isomeric SMILESNc1nc2n(CCC(CO)CO)cnc2c(=O)[nH]1
InChIInChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18)
InChIKeyJNTOCHDNEULJHD-UHFFFAOYSA-N

Chemical Details

Formal Charge0
Atom Count33
Chiral Atom Count0
Chiral Atomsn/a
Bond Count34
Aromatic Bond Count5
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB00299 Different stereochemistry
NamePenciclovir
Groupsapproved
DescriptionPenciclovir is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. [Wikipedia]
Synonyms
  • 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine
  • 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine
  • 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine
  • 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine
  • PCV
SaltsPenciclovir sodium
Brand Names
  • Denavir
  • Penciclovir
Affected OrganismHerpes simplex virus
IndicationUsed to treat recurrent cold sores on the lips and face from various herpesvirus invections.
PharmacologyPenciclovir is the active metabolite of the oral product famciclovir. The more favorable results observed with topical penciclovir versus topical acyclovir for the treatment of herpes labialis may be due to the longer intracellular half-life of penciclovir in HSV-infected cells. The activated drug inhibits the viral DNA polymerase. This impairs the ability of the virus to replicate within the cell.
Mechanism of actionPenciclovir has <i>in vitro</i> activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form. The monophosphate form of the drug is then converted to penciclovir triphosphate by cellular kinases. The intracellular triphosphate of penciclovir is retained <i>in vitro</i> inside HSV-infected cells for 10-20 hours, compared with 0.7-1 hour for acyclovir. <i>in vitro</i> studies show that penciclovir triphosphate selectively inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. Inhibition of DNA synthesis of virus-infected cells inhibits viral replication. In cells not infected with HSV, DNA synthesis is unaltered. Resistant mutants of HSV can occur from qualitative changes in viral thymidine kinase or DNA polymerase. The most commonly encountered acyclovir-resistant mutants that are deficient in viral thymidine kinase are also resistant to penciclovir.
Route of administrationTopical
Categories
  • Anti-Infective Agents
  • Antiinfectives for Systemic Use
  • Antiviral Agents
  • Antivirals for Systemic Use
  • Chemical Actions and Uses
ATC-Code
  • D06BB06
  • J05AB13
AHFS-Code84:04.06
CAS number39809-25-1
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682